A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments.
Study Goal
The researchers aimed to determine whether melatonin coadministration reduces fatigue in breast cancer patients undergoing adjuvant chemotherapy and radiotherapy.
Results Summary
The study found that melatonin significantly reduced fatigue levels (measured by BFI scores) in breast cancer patients compared to placebo after adjuvant treatment.
Population
Women with breast cancer undergoing adjuvant chemotherapy and radiotherapy.
Effective Dosage
Not specified
Duration
Duration of adjuvant chemotherapy and radiotherapy (not explicitly stated)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin coadministration | decrease | levels of fatigue associated with the malignant condition and its treatments | women with breast cancer | - | decreased | #1 |
melatonin | decrease | BFI score | patients with breast cancer | - | significantly lower | #2 |
OBJECTIVE: Fatigue associated with malignant conditions and their treatments is a disabling condition. This trial assessed the anti-fatigue effects of melatonin coadministration during adjuvant treatment of patients with the breast cancer. MATERIAL AND METHODS: Patients with breast cancer were randomly assigned to receive melatonin or placebo during adjuvant chemotherapy and radiotherapy. Thirty-seven patients were randomly enrolled in each group. The mean ages of patients in the intervention and control groups were 50.47 ± 10.79 and 46.05 ± 10.55 years, respectively ( RESULTS: The BFI score was similar before the intervention in both groups, however, after the intervention, it was significantly lower in the melatonin group ( CONCLUSION: Coadministration of melatonin during adjuvant chemotherapy and radiotherapy of women with breast cancer decreased the levels of fatigue associated with the malignant condition and its treatments.